Compare Delta Air Lines, Inc. (DAL) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Eli Lilly And Co — how do they compare? Delta Air Lines, Inc. trades at $81.73 (market cap $54.02B), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 19.3× Delta Air Lines, Inc.'s market cap, and Delta Air Lines, Inc. pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Eli Lilly And Co for 93 Days on average.
| DAL | LLY | |
|---|---|---|
Market Cap | $54.02B | $1.04T |
Volume | 9,632,845 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $93.66 | $1.28K |
52-Week Low | $55.65 | $799.57 |
Typical Hold Time | 97 Days | 93 Days |
Enterprise Value | $69.34B | $1.09T |
Dividend Yield | 1.05% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $63.36 billion in 2025, while profitability metrics remain solid with a 5.78% net income margin and 20.12% ROE. Analyst sentiment remains overwhelmingly positive with 82% buy ratings and a $103.36 consensus price target representing 25% upside potential.
DAL presents a compelling investment case with attractive valuation multiples (P/E of 13.76, P/S of 0.8) and strong cash flow generation, though near-term headwinds include fuel cost volatility and competitive pressures. The stock's technical weakness contrasts with fundamental strength, creating potential opportunity for patient investors. Key risks include oil price sensitivity and execution challenges in maintaining premium customer loyalty against aggressive competitor tactics.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
